alexa
Reach Us +1-218-451-2974
Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Dise ase Pathologies | OMICS International | Abstract
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Dise ase Pathologies

Ming Tong1,2,4, Cesar Dominguez8, John Didsbury9 and Suzanne M de la Monte1-7*

1Liver Research Center, Warren Alpert Medical School of Brown University, Providence, RI, USA

2Divisions of Gastroenterology, Warren Alpert Medical School of Brown University, Providence, RI, USA

3Department of Neuropathology, Warren Alpert Medical School of Brown University, Providence, RI, USA

4Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA

5Department of Pathology, Warren Alpert Medical School of Brown University, Providence, RI, USA

6Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA

7Department of Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI,

8Williams College, Williams, MA, USA

9T3D Pharmaceuticals, Raleigh Durham, NC, USA5Australian School of Advanced Medicine, Macquarie University, Sydney, Australia

*Corresponding Author:
Suzanne M de la Monte
Pierre Galletti Research Building, Rhode Island Hospital
55 Claverick Street, Room 419, Providence, RI, USA
Tel: 401-444-7364
Fax: 401-444-2939
E-mail: [email protected]

Received date: May 02, 2016; Accepted date: May 27, 2016; Published date: June 03, 2016

Citation: Tong M, Dominguez C, Didsbury J, de la Monte SM (2016) Targeting Alzheimer’s Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism 6:238. doi: 10.4172/2161-0460.1000238

Copyright: © 2016 Tong M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Alzheimer’s disease (AD) could be regarded as a brain form of diabetes since insulin resistance and deficiency develop early and progress with severity of neurodegeneration. Preserving insulin’s actions in the brain restores function and reduces neurodegeneration. T3D-959 is a dual nuclear receptor agonist currently in a Phase 2a trial in mild-to-moderate AD patients (ClinicalTrials.gov identifier NCT02560753). Herein, we show that T3D-959 improves motor function and reverses neurodegeneration in a sporadic model of AD.

Methods: Long Evans rats were administered intracerebral (i.c.) streptozotocin (STZ) or normal saline (control) and dosed orally with T3D-959 (1.0 mg/kg/day) or saline for 21 or 28 days. Rotarod tests evaluated motor function. Histopathology with image analysis was used to assess neurodegeneration.

Results: T3D-959 significantly improved motor performance, and preserved both cortical and normalized white matter structure in i.c STZ-treated rats. T3D-959 treatments were effective when dosed therapeutically, whether initiated 1 day or 7 days after i.c. STZ.

Conclusion: T3D-959’s targeting neuro-metabolic dysfunctions via agonism of PPAR delta and PPAR gamma nuclear receptors provides potential disease modification in AD.

Keywords

Recommended Conferences

14th International Conference on Alzheimer s Disease & Dementia

Zurich, Switzerland

12th World Congress on Alzheimers Disease & Dementia

Budapest, Hungary
Share This Page
Top